Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) CEO Scott Hutton sold 83,660 shares of Biodesix stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $76,967.20. Following the completion of the transaction, the chief executive officer now owns 701,947 shares in the company, valued at $645,791.24. This trade represents a 10.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Biodesix Stock Up 2.3 %
BDSX traded up $0.02 on Friday, hitting $0.99. The company had a trading volume of 199,585 shares, compared to its average volume of 496,630. The stock has a fifty day moving average price of $1.23 and a 200-day moving average price of $1.48. Biodesix, Inc. has a 12-month low of $0.86 and a 12-month high of $2.04. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. The stock has a market capitalization of $143.28 million, a price-to-earnings ratio of -2.53 and a beta of 1.06.
Hedge Funds Weigh In On Biodesix
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC grew its stake in Biodesix by 8.8% in the fourth quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company's stock valued at $9,455,000 after purchasing an additional 500,000 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Biodesix in the third quarter valued at about $10,849,000. Birchview Capital LP grew its stake in Biodesix by 0.7% in the fourth quarter. Birchview Capital LP now owns 5,581,176 shares of the company's stock valued at $8,539,000 after purchasing an additional 40,000 shares during the last quarter. Silverarc Capital Management LLC grew its stake in Biodesix by 21.7% in the fourth quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company's stock valued at $6,628,000 after purchasing an additional 771,187 shares during the last quarter. Finally, Samjo Management LLC purchased a new position in Biodesix in the fourth quarter valued at about $3,790,000. Hedge funds and other institutional investors own 20.96% of the company's stock.
About Biodesix
(
Get Free Report)
Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
See Also
Before you consider Biodesix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.
While Biodesix currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
